SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)

SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)

SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)

SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)

SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

ZÜRICH, SWITZERLAND / ACCESSWIRE / November 18, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, provided insights today into the preclinical program evaluating its dual orexin receptor agonist (DOXA) platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed to target both orexin-1 (OX1R) and orexin-2 (OX2R) receptors while concurrently inhibiting cathepsins. This unique approach aims to address the unmet therapeutic needs in narcolepsy and related neur

ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA") ("Kadimastem"), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announced today that they have entered into a definitive merger agreement (the "Merger Agreement") to combine the two companies to focus on advancing NLS' promising, first-in class Dual Orexin Agonist platform ("DOXA") and Kadimastem's allogenic cell therapy program with its clinical assets (mainly targeti

ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has received notice from the Nasdaq Stock Market LLC ("NASDAQ") informing the Company that it has regained full compliance with the bid price requirement in Listing Rule 5550(a)(2) and the equity requirement in Listing Rule 5550(b)(1)."We are pleased to report that Nasdaq has recognized our full compliance with their listing requirements," said Alex Zwyer, Chi

ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is pleased to announce that its Japanese patent application No. 2020-513594 has been granted. The patent covers the use of Mazindol ER (extended-release) for the treatment of heroin dependence, providing a new therapeutic strategy for opioid use disorder."The development of mazindol as a treatment for substance use disorder could represent a significant breakthrough, offering new hope for patients battling addiction. It is cruc

ZURICH, SWITZERLAND / ACCESSWIRE / October 15, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the closing of a private placement offering consisting of the issuance and sale of 806,452 common shares, par value CHF 0.80 per share and common share purchase warrants to purchase 806,452 common shares, at a combined purchase price of $3.97, for aggregate gross proceeds of $3.2 million. The warrants have a term of five years and have an exercise price of $4.25 per s

ZURICH, SWITZERLAND / ACCESSWIRE / September 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that a reverse share split of the Company's issued and outstanding common shares, par value CHF 0.02 per share (the "Common Shares"), at a ratio of 1-for-40 is expected to be implemented at market open on September 27, 2024 (the "Reverse Split"). The Company's Common Shares are expected to begin trading on the Nasdaq Capital Market on a post-split basis at the marke

The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platformEach of Kadimastem and NLS Pharmaceutics has received commitments of support for the transaction from shareholders representing more than 40% of their respective outstanding shares ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / July 29, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company. and Kadimastem Ltd ("KDST.TA", "Kadimastem"), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for

ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,277,750 of its common shares at a purchase price of $0.24 per share in a registered direct offering. NLS has also agreed to issue in a private placement unregistered warrants to purchase up to an aggregate of 3,277,750 common shares at an exercise price of $0.24 per share. The

ZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced preclinical results from multiple in vitro studies targeting alpha-synuclein (α-synuclein), specifically the A53T mutation, that demonstrate the compounds' potential to advance the treatment of Parkinson's Disease (PD). The compounds may be used by NLS pursuant to its existing and previously announced license agreement with Aexon Labs, Inc. (Aexon Labs or AEX)."These in vitro results obtained from various Aexon Lab

ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today that it received notice from the Nasdaq Hearings Panel ("Panel") of The Nasdaq Stock Market ("Nasdaq") that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market, as discussed more fully below.Subject to the Company meeting certain financial, share price and other requirements by September 3, 2024 and October 14, 2024, the Panel granted the Compa

F-3/A - NLS Pharmaceutics Ltd. (0001783036) (Filer)

6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)

6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)

6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)

6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)

6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)

425 - NLS Pharmaceutics Ltd. (0001783036) (Subject)

6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)

425 - NLS Pharmaceutics Ltd. (0001783036) (Subject)

6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)

Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disordersProfessor Florence Allouche Aknin, PharmD, MBA, is a professor at University Paris City, specializing in pharmaceutical innovation, entrepreneurship and fundraisingZURICH, SWITZERLAND / ACCESSWIRE / November 28, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that, subject to final ap

ZURICH, SWITZERLAND / ACCESSWIRE / August 28, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:NLS Pharmaceutics CEO Issues Letter to ShareholdersTo our Shareholders and Friends,Though we may have been quiet recently, I wanted to assure you that the team here at NLS has been very busy behind the scenes ensuring that we realize our vision of awakening a brighter future for pa

ZÜRICH, SWITZERLAND / ACCESSWIRE / May 8, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that Keith Harrison Dewedoff has been appointed to the position of Interim Chief Financial Officer ("CFO"). A versatile strategic leader within healthcare, Mr. Dewedoff brings more than 20 years of experience in the life sciences industry, ranging from biotech venture-backed start-ups to commercial publicly traded companies. Mr. Dewedoff also serves as a CFO and Advisor fo

Company also announces expected departure of Sylvia Panigone, Ph.D.ZURICH, SWITZERLAND / ACCESSWIRE / September 8, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Dr. George Apostol has been appointed to the position of Chief Medical Officer and Global Head of Research and Development ("R&D"). Serving most recently as Global Head of Research and Development at Endo Pharmaceuticals Inc. ("Endo"), Dr. Apostol brings significant expertise in the management and execution

ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Chad C. Hellmann has been appointed to the position of Chief Financial Officer ("CFO"). Serving most recently as CFO and co-portfolio manager of Arcus Ventures, Mr. Hellmann brings to NLS significant expertise in developing and implementing operational strategies and capital markets solutions for life sciences companies. NLS also announces that Subhasis Roy has resigned a

STANS, SWITZERLAND / ACCESSWIRE / July 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (CNS) disorders, announces the appointment of Eric Konofal, M.D., Ph.D., as Chief Scientific Officer. Dr. Konofal is a co-founder and has over 30 years of experience as a physician and leading researcher in the field of sleep disorders and other CNS diseases."As a co-founder of NLS, Eric has already made enormous contributions to the Company with regard to our early work on Quilience® and Nolazol®, and now he is able to fully

STANS, Switzerland, April 5, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the appointment of Silvia Panigone, Ph.D., eMBA as Chief Operating Officer. Dr. Panigone brings to NLS over 25 years of leadership experience in the healthcare industry, founding and operating ADYA Consulting, a boutique advisory firm that provides strategic counseling, access to capital, and M&A advisory services to companies in the life sciences sector, and serving in operational and

Brookline Capital initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $12.00

Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $8.00

Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $8.00

Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy

Key findingsAEX-23: Its pronounced action as an OX1R agonist combined with positive effects on neurite outgrowth at specific concentrations suggests that it may modulate neuronal health through pathways influencing α-synuclein dynamics, making it a potential therapeutic candidate to improve neuronal connectivity and resilience in PD.AEX-19: Its effects at low concentrations on neurite growth coupled with OX1R agonist activity and a moderate increase in CTSD activity suggest potential neuroprotective benefits in PD.AEX-24: The increase in CTSD activity and agonist activity on OX1R suggests the potential to enhance α-synuclein degradation, highlighting its promising therapeutic impact on PD.

Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA

U.S. stocks traded mixed this morning, with the S&P 500 gaining around 0.1% on Thursday. Following the market opening Thursday, the Dow traded down 0.10% to 38,795.35 while the NASDAQ rose 0.16% to 17,890.82. The S&P 500 also rose, gaining, 0.12% to 5,493.76. Check This Out: Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday Leading and Lagging SectorsFinancial shares jumped by 0.6% on Thursday. In trading on Thursday, communication services shares fell by 0.8%. Top Headline The U.S. current account deficit rose by $15.8 billion to $237.6 billion during the first quarter, and versus market estimates of a $206.4 billion gap. Equities Trading UP    

Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses. Vuzix shares jumped 15% to $1.53 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers SMX (Security Matters) Public Limited Company (NASDAQ:SMX) rose 109.8% to $0.2497 in pre-market trading after jumping 19% on Tuesday. Selina Hospitality PLC (NASDAQ:SLNA) gained 46.9% to $0.1024 in pre-market trading after declining 7% on Tuesday. Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 44.5%

Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Quantum shares dipped 44.5% to $0.43 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Reliance Global Group, Inc. (NASDAQ:RELI) shares jumped 350% to $1.00 after the company issued an update on the pending acquisition of Spetner Associates. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 166% to $0.3930 after jumping 30% on Monday. Actelis Networks, Inc. (NASDAQ:ASNS) climbed 80.9% to $2.08 after the company announced a partnership with Carahsoft Tech

U.S. stocks traded mixed this morning, with the Nasdaq Composite edging lower on Tuesday. Following the market opening Tuesday, the Dow traded up 0.25% to 38,875.50 while the NASDAQ fell 0.12% to 17,836.13. The S&P 500 also rose, gaining, 0.15% to 5,481.48. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 8% Dividend Yields Leading and Lagging SectorsEnergy shares jumped by 1.6% on Tuesday. In trading on Tuesday, consumer discretionary shares fell by 0.4%. Top Headline U.S. retail sales rose 0.1% month-over-month in May compared to a revised 0.2% declined in April and missing market expectations of 0.2% gain. Equities Tradi

Shares of Chegg, Inc. (NYSE:CHGG) rose sharply in today's pre-market trading after the company announced a restructuring plan and new vision for growth. The restructuring plan will include a 23% headcount reduction, a refocus on students with a comprehensive course load and dedication of more resources to its international program. Chegg shares jumped 20.7% to $3.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) rose 112.2% to $2.44 in pre-market trading after the company announced a partnership with Carahsoft Technology Corp. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 62.8% to $0